v3.26.1
Collaboration and License Agreements - Sarepta Therapeutics, Inc. (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 13, 2025
USD ($)
shares
Feb. 14, 2025
USD ($)
Feb. 07, 2025
USD ($)
Nov. 25, 2024
USD ($)
program
payment
obligation
Feb. 28, 2026
USD ($)
Nov. 30, 2025
USD ($)
Aug. 31, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
obligation
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Treasury stock value               $ 53,193 $ 53,193   $ 53,193  
Revenue               75,253   $ 27,767 413,023 $ 572,976
Accounts receivable               8,556 6,824   8,556  
Contract assets               10,231 0   10,231  
Contract liabilities included in deferred revenue, current               94,596 2,399 $ 22,979 94,596 $ 22,979
Sarepta                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Accounts receivable               5,000     5,000  
Contract assets               $ 10,200     10,200  
Sarepta | Sarepta Collaboration Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Number of performance obligations | obligation       17                
Upfront payment $ 50,000 $ 500,000     $ 50,000   $ 50,000   50,000      
Net proceeds from sale of stock     $ 325,000                  
Equity premium     $ 83,600                  
Annual fees       $ 250,000                
Annual installment       $ 50,000                
Annual installments period       5 years                
Total transaction price       $ 904,900                
Fixed consideration       833,600                
Variable consideration       $ 71,200                
Development milestone payments           $ 200,000 100,000   100,000      
Value of stock repurchased $ 50,000           $ 50,000   $ 50,000      
Number of development milestone payments | payment       2                
Number of collaboration programs | program       13                
Collaboration agreement termination notice period prior to any regulatory approval of a licensed product       30 days                
Common stock repurchased (in shares) | shares 2,660,989           2,660,989          
Treasury stock value $ 53,200           $ 53,200          
Gain on settlement of treasury stock $ 3,200           $ 3,200          
Number of distinct performance obligations | obligation               4        
Revenue               $ 26,000     292,800  
Sarepta | Sarepta Clinical Supply Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue               $ 400     $ 4,700  
Sarepta | Maximum | Sarepta Collaboration Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Number of new target programs | program       6                
Regulatory milestone payments       $ 180,000                
Sales-related milestone payments       700,000                
Sarepta | Minimum | Sarepta Collaboration Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Regulatory milestone payments       110,000                
Sales-related milestone payments       $ 500,000